States face lobbying from drugmakers to restrict biosimilars

01/29/2013 | New York Times (tiered subscription model), The

Amgen and Genentech are among the drugmakers pushing state legislatures to restrict substitution of biosimilar drugs for branded biologic therapies. Bills under consideration would require patient consent and doctor notification before a biosimilar may be substituted and would mandate that only drugs deemed "interchangeable" by the FDA could be substituted.

View Full Article in:

New York Times (tiered subscription model), The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN